PTPRK
PTPRK (Receptor-type tyrosine-protein phosphatase kappa) is an enzyme. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Breast cancer, Bladder & urothelial cancer, Renal cell carcinoma and 5 more.
Overview
Regulation of processes involving cell contact and adhesion such as growth control, tumour invasion, and metastasis. Negative regulator of EGFR signalling pathway. Forms complexes with beta-catenin and gamma-catenin/plakoglobin.
Open Targets scores its association with cancer at 0.72 (direct and indirect evidence; datatypes literature 0.93, animal model 0.59, genetic association 0.50, somatic mutation 0.85). IntOGen calls it a driver in 3 cohorts (1 activating, 2 loss-of-function), covering Bladder Urothelial Carcinoma, Renal Clear Cell Carcinoma, Non-Small Cell Lung Cancer.
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · PTPRK (Receptor-type tyrosine-protein phosphatase kappa) is an enzyme. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Breast cancer, Bladder & urothelial cancer, Renal cell carcinoma and 5 more.
- 1 · What it is
PTPRK (Receptor-type tyrosine-protein phosphatase kappa) is an enzyme. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Breast cancer, Bladder & urothelial cancer, Renal cell carcinoma and 5 more.
- 2 · What goes wrong in cancer
Regulation of processes involving cell contact and adhesion such as growth control, tumour invasion, and metastasis. Negative regulator of EGFR signalling pathway.
- 3 · How drugs use it
No product in this corpus aims at PTPRK yet. Inhibitors are shaped to fit the enzyme's active site so the reaction the cancer relies on stops.
External identifiers
Sources: HGNC HGNC:9674 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q15262 (protein name, function text, keywords and locations (REST API)); Open Targets ENSG00000152894 (association with cancer (MONDO_0004992) 0.72; per-cancer scores at or above 0.5: colorectal cancer 0.55, melanoma 0.58, skin cancer 0.56, breast cancer 0.57 (GraphQL API, CC0)); IntOGen PTPRK (driver in 3 cohorts (Act 1, LoF 2); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Biology
Regulation of processes involving cell contact and adhesion such as growth control, tumour invasion, and metastasis. Negative regulator of EGFR signalling pathway. Forms complexes with beta-catenin and gamma-catenin/plakoglobin. Beta-catenin may be a substrate for the catalytic activity of PTPRK/PTP-kappa. Location: Cell junction, adherens junction; Cell membrane (UniProt). Locus 6q22.33 (HGNC).
- Breast cancer: Open Targets association 0.57 with breast cancer (MONDO_0007254)
- Bladder & urothelial cancer: IntOGen driver in 1 cohort (BLCA)
- Renal cell carcinoma: IntOGen driver in 1 cohort (CCRCC)
- Skin cancer: Open Targets association 0.56 with skin cancer (MONDO_0002898)
- Colorectal cancer: Open Targets association 0.55 with colorectal cancer (MONDO_0005575)
- Melanoma: Open Targets association 0.58 with melanoma (MONDO_0005105)
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: IntOGen calls it an activating (Act) driver in 1 cohort; IntOGen calls it a loss-of-function (LoF) driver in 2 cohorts. Evidence tier "cohort-driver" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
Latest papers
topQuery for this target: (TITLE:"PTPRK" OR ABSTRACT:"PTPRK" OR TITLE:"protein tyrosine phosphatase receptor type K" OR ABSTRACT:"protein tyrosine phosphatase receptor type K" OR TITLE:"Receptor-type tyrosine-protein phosphatase kappa" OR ABSTRACT:"Receptor-type tyrosine-protein phosphatase kappa" OR TITLE:"R-PTP-kappa" OR ABSTRACT:"R-PTP-kappa") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about PTPRK, not a curated reading list.
Similar pages
not linked directly; found by shared links- TargetARHGEF12
Shares Clear cell renal cell carcinoma, Skin cancer (all types), Renal cell carcinoma, Breast cancer (all types).
- TargetRANBP2
Shares Clear cell renal cell carcinoma, Skin cancer (all types), Renal cell carcinoma, Breast cancer (all types).
- TargetCHD4
Shares Clear cell renal cell carcinoma, Skin cancer (all types), Renal cell carcinoma, IntOGen.
- TargetCLTC
Shares Clear cell renal cell carcinoma, Renal cell carcinoma, Bladder & urothelial cancer, Breast cancer (all types).
- TargetKDM5C
Shares Clear cell renal cell carcinoma, Skin cancer (all types), Renal cell carcinoma, IntOGen.
- TargetRAP1GDS1
Shares Clear cell renal cell carcinoma, Renal cell carcinoma, Breast cancer (all types), IntOGen.
- TargetATG7
Shares Clear cell renal cell carcinoma, Renal cell carcinoma, IntOGen, Open Targets Platform.
- TargetARHGEF10L
Shares Clear cell renal cell carcinoma, Renal cell carcinoma, IntOGen.